AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35176764 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN1046 (DuoBody-PD-L1×4-1BB)
Number of subjects: 61
Study 35176918 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioVac System
Number of subjects: 0
Study 35177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic phenotype (≥ 300 cells/mm)
Number of subjects: 101
Study 35177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic phenotype 1
Number of subjects: 101
Study 35177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic overlap (eosinophilic and atopic 1)
Number of subjects: 101
Study 35177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic phenotype 2
Number of subjects: 101
Study 35177038 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic overlap (eosinophilic and atopic 2)
Number of subjects: 101
Study 35177038 — intervention group
Group type: COMPARATOR
Intervention: Asthma control and oral corticosteroid use patterns
Number of subjects: 101
Study 35177040 — intervention group
Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention
Number of subjects: 135
Study 35177200 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary Spinal Cord Stimulation
Number of subjects: 0
Study 35177200 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35177252 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade I
Number of subjects: 1270
Study 35177252 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade II
Number of subjects: 1270
Study 35177252 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade III
Number of subjects: 1270
Study 35177252 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade IV
Number of subjects: 1270
Study 35177252 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra grade
Number of subjects: 1270
Study 35177252 — intervention group
Group type: COMPARATOR
Intervention: Visceral surgery
Number of subjects: 1270
Study 35177293 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate dietary protein with whey protein, leucine, and vitamin D supplementation
Number of subjects: 0
Study 35177293 — intervention group
Group type: COMPARATOR
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 0
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer vaccine
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderna vaccine
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: J&J vaccine
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with autoimmune disease
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with lung disease
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants vaccinated against influenza
Number of subjects: 6966
Study 35177299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall side effect burden
Number of subjects: 6966
Study 35177415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tumor-infiltrating lymphocytes (TILs) after modified lymphodepleting regimen
Number of subjects: 1
Study 35177415 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lymphodepleting regimen including intravenous cyclophosphamide (20 mg/kg for 3 days) and half dosage (100 mg) of PD1 antibody
Number of subjects: 1
Study 35177415 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-course peripheral blood counts and TCR repertoire sequencing
Number of subjects: 1
Study 35177453 — intervention group
Group type: EXPERIMENTAL
Intervention: Open appendectomy for children without appendiceal mass and/or abscess
Number of subjects: 1308
Study 35177453 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy for children without appendiceal mass and/or abscess
Number of subjects: 1308
Study 35177453 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial non-operative treatment (intravenous antibiotics with or without percutaneous drainage) for children with appendiceal mass and/or abscess
Number of subjects: 1308
Study 35177453 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct appendectomy for children with appendiceal mass and/or abscess
Number of subjects: 1308
Study 35177453 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 1308
Study 35177453 — intervention group
Group type: EXPERIMENTAL
Intervention: (In)direct costs
Number of subjects: 1308
Study 35177461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk protein elimination diet with amino acid-based formula for 14 days
Number of subjects: 300
Study 35177461 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CoMiSS of ≥12
Number of subjects: 300
Study 35177461 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operator characteristic (ROC) analysis
Number of subjects: 300
Study 35178068 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing for genetic diagnosis
Number of subjects: 0
Study 35178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant follow-up for a mean duration of 7.22 years
Number of subjects: 107
Study 35178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant characteristics including location, bone level, and number
Number of subjects: 107
Study 35178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented retention and emergence restoration profile
Number of subjects: 107
Study 35178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical peri-implant and periodontal soft tissue statuses
Number of subjects: 107
Study 35178092 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implant parameters
Number of subjects: 107
Study 35178428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM) followed by radiotherapy (45-50.4 Gy in 25-28 fractions)
Number of subjects: 168
Study 35178428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM) followed by radiotherapy
Number of subjects: 168
Study 35178428 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 168
Study 35178432 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 155
Study 35178432 — intervention group
Group type: COMPARATOR
Intervention: Printed messages group
Number of subjects: 155
Study 35178652 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-targeted, fear-appeal messages designed using the Extended Parallel Processing Model (EPPM) highlighting HPV-related cancers or genital warts.
Number of subjects: 0
Study 35178652 — intervention group
Group type: COMPARATOR
Intervention: Control messages (not specified in detail).
Number of subjects: 0
Study 35178889 — intervention group
Group type: COMPARATOR
Intervention: S (sarcopenic)
Number of subjects: 22
Study 35179437 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapies in pregnancy
Number of subjects: 0
Study 35179437 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception counseling and continued monitoring
Number of subjects: 0
Study 35179437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic markers and targeted immunosuppression
Number of subjects: 0
Study 35179502 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone app) encouraging reduction of alcohol consumption
Number of subjects: 357
Study 35179502 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone app)
Number of subjects: 357
Study 35179564 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 602
Study 35179564 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 ARDS
Number of subjects: 602
Study 35179726 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsive exercise
Number of subjects: 4262
Study 35179726 — intervention group
Group type: EXPERIMENTAL
Intervention: Body dissatisfaction
Number of subjects: 4262
Study 35179726 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender difference in body dissatisfaction
Number of subjects: 4262
Study 35179774 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35180010 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (50 mg once daily, escalating to a maximum of 300 mg once daily)
Number of subjects: 34
Study 35180010 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib (≥ 10 mg twice daily)
Number of subjects: 34
Study 35180296 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group
Number of subjects: 167
Study 35180296 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance group
Number of subjects: 167
Study 35180323 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and vorinostat with FLAG chemotherapy (fludarabine, cytarabine, and G-CSF)
Number of subjects: 37
Study 35180323 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and vorinostat with FLAG chemotherapy
Number of subjects: 37
Study 35180412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0
Study 35180771 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m2 Q3W
Number of subjects: 21
Study 35180771 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF 1.5 mg/m2 Q2W
Number of subjects: 21
Study 35180771 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m2 Q3W and 1.5 mg/m2 Q2W
Number of subjects: 21
Study 35180771 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF
Number of subjects: 21
Study 35181266 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 544
Study 35181266 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 544
Study 35181266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SPPB and MoCA
Number of subjects: 544
Study 35181266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living (IADL)
Number of subjects: 544
Study 35181498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711) at doses of 30 mg, 60 mg, 120 mg, 180 mg, 240 mg, 300 mg once daily until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 172
Study 35181498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711)
Number of subjects: 172
Study 35181499 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily) plus durvalumab (3 or 10 mg/kg every 2 weeks) in part A
Number of subjects: 34
Study 35181499 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus durvalumab (10 mg/kg every 2 weeks) in part B
Number of subjects: 34
Study 35181519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated designs with FG ≥5 mm
Number of subjects: 430
Study 35181519 — intervention group
Group type: COMPARATOR
Intervention: Fenestrations with FG ≥5 mm
Number of subjects: 430
Study 35181519 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced fenestrations
Number of subjects: 430
Study 35181519 — intervention group
Group type: COMPARATOR
Intervention: DBs
Number of subjects: 430
Study 35181541 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0
Study 35181541 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study 35181666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib and fulvestrant combination therapy
Number of subjects: 5
Study 35181700 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal set of biomarkers selected by LASSO (NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, transferrin receptor protein-1, chitotriosidase-1)
Number of subjects: 250
Study 35181700 — intervention group
Group type: COMPARATOR
Intervention: Standard biomarkers (NT-proBNP, hs-TnT, eGFR clinically adjusted)
Number of subjects: 250
Study 35181700 — intervention group
Group type: COMPARATOR
Intervention: Extended literature-based set of acknowledged biomarkers (NT-proBNP, hs-TnT, hs-CRP, GDF-15, ST2, PAI-1, Galectin 3)
Number of subjects: 250
Study 35182224 — intervention group
Group type: EXPERIMENTAL
Intervention: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.4 mg/kg
Number of subjects: 36
Study 35182224 — intervention group
Group type: EXPERIMENTAL
Intervention: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.8 mg/kg
Number of subjects: 36
Study 35182224 — intervention group
Group type: EXPERIMENTAL
Intervention: R-atezo-pola (rituximab, atezolizumab, polatuzumab vedotin)
Number of subjects: 36
Study 35182224 — intervention group
Group type: EXPERIMENTAL
Intervention: G-atezo-pola
Number of subjects: 36
Study 35182224 — intervention group
Group type: EXPERIMENTAL
Intervention: R-atezo-pola
Number of subjects: 36
Study 35182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) for hepatitis C
Number of subjects: 0
Study 35183106 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Index (FI)
Number of subjects: 598
Study 35183106 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Rankin Scale (mRS)
Number of subjects: 598
Study 35183133 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based real-life lifestyle program 'Lekker Actief' including a progressive walking program, optional muscle strengthening program, and educational session on healthy nutrition.
Number of subjects: 451
Study 35183133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 451
Study 35183167 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab therapy
Number of subjects: 205
Study 35183221 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy interruption due to Spring Festival holidays
Number of subjects: 5035
Study 35183221 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of radiotherapy interruption during Spring Festival
Number of subjects: 5035
Study 35183221 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of concurrent chemotherapy (CC)
Number of subjects: 5035
Study 35183221 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated dose of cisplatin < 200 mg
Number of subjects: 5035
Study 35183261 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS-enhanced inhibitory control training
Number of subjects: 40
Study 35183261 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control condition)
Number of subjects: 40
Study 35183442 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNγ-stimulated bone marrow-derived mesenchymal stromal cells (BM-MSCs) injected into the submandibular gland.
Number of subjects: 30
Study 35183442 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNγ-stimulated BM-MSCs
Number of subjects: 30
Study 35183451 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary Gastric Electrical Stimulation (tGES)
Number of subjects: 1345
Study 35183477 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of thoracic aortic calcium volume after 12.7 ± 2.7 months
Number of subjects: 0
Study 35183478 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCT analysis
Number of subjects: 303
Study 35183478 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCT evaluation
Number of subjects: 303
Study 35183478 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCT findings
Number of subjects: 303
Study 35183775 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 329
Study 35184142 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) ≥150 mmHg and 10-year predicted ASCVD risk <20%
Number of subjects: 7426
Study 35184142 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) ≥150 mmHg and 10-year predicted ASCVD risk 20-34%
Number of subjects: 7426
Study 35184142 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) ≥150 mmHg and 10-year predicted ASCVD risk ≥35%
Number of subjects: 7426
Study 35184256 — intervention group
Group type: EXPERIMENTAL
Intervention: DM1157
Number of subjects: 0
Study 35184428 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluations including clinical dementia rating-sum of boxes (CDR-SOB)
Number of subjects: 25
Study 35184825 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews and focus group discussions addressing social norms and child marriage
Number of subjects: 20
Study 35184825 — intervention group
Group type: EXPERIMENTAL
Intervention: Efforts to reduce child marriage through education and economic opportunities
Number of subjects: 20
Study 35185515 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation (tDCS) administered by study companions, 37 sessions over 12 weeks.
Number of subjects: 0
Study 35185515 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for study companions to administer tDCS remotely.
Number of subjects: 0
Study 35185579 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangtang Tiaozhi Recipe
Number of subjects: 0
Study 35185746 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Dance for PD (10-h weekly sessions)
Number of subjects: 23
Study 35185883 — intervention group
Group type: EXPERIMENTAL
Intervention: IKKβ-matured, RNA-loaded dendritic cells
Number of subjects: 0
Study 35185912 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL1 expression in mesothelial cells
Number of subjects: 56
Study 35185912 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal microvessel density
Number of subjects: 56
Study 35186075 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG247 Smart Heart Sensor
Number of subjects: 97
Study 35186075 — intervention group
Group type: COMPARATOR
Intervention: Standard 12-lead ECG
Number of subjects: 97
Study 35186075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems (ECG247 Smart Heart Sensor and standard 12-lead ECG)
Number of subjects: 97
Study 35186258 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-monthly (PP3M)
Number of subjects: 0
Study 35186305 — intervention group
Group type: EXPERIMENTAL
Intervention: HBPT + case management
Number of subjects: 100
Study 35186305 — intervention group
Group type: COMPARATOR
Intervention: HBPT + usual care
Number of subjects: 100
Study 35186675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metabolic surgery (gastric bypass) plus medical therapy (CSM)
Number of subjects: 0
Study 35186675 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (MTA)
Number of subjects: 0
Study 35187036 — intervention group
Group type: EXPERIMENTAL
Intervention: DGA-conforming diet (DGAD) with 240 g/wk of salmon and albacore tuna
Number of subjects: 0
Study 35187036 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 0
Study 35187107 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteins involved in vascular processes (MYO and C-C-22)
Number of subjects: 544
Study 35187107 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteins involved in vascular processes (PS-3 and PAF-AH)
Number of subjects: 544
Study 35187168 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive simulated jogging device (JD) for 90 minutes per day for 7 days
Number of subjects: 21
Study 35187168 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive simulated jogging device (JD)
Number of subjects: 21
Study 35187383 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 28
Study 35187383 — intervention group
Group type: EXPERIMENTAL
Intervention: intramuscular low-dose testosterone
Number of subjects: 28
Study 35187395 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending intervention
Number of subjects: 0
Study 35187396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phosphorus load
Number of subjects: 0
Study 35187396 — intervention group
Group type: EXPERIMENTAL
Intervention: Food matrix
Number of subjects: 0
Study 35187490 — intervention group
Group type: EXPERIMENTAL
Intervention: Online palliative rehabilitation program
Number of subjects: 16
Study 35187490 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregivers' coping strategies
Number of subjects: 16
Study 35187490 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals' coping strategies
Number of subjects: 16
Study 35187671 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (GE)
Number of subjects: 1563
Study 35187671 — intervention group
Group type: COMPARATOR
Intervention: Normal gastric emptying (GE)
Number of subjects: 1563
Study 35187951 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib, Letrozole, and Venetoclax combination therapy
Number of subjects: 0
Study 35187951 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy with a CDK4/6 inhibitor (gold standard treatment)
Number of subjects: 0
Study 35188473 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus LiveWell (smartphone-based self-management intervention)
Number of subjects: 205
Study 35188473 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 35188608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 35188911 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 1
Study 35189157 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 9 Gy prostate cancer SABR
Number of subjects: 219
Study 35189168 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-Architect
Number of subjects: 392
Study 35189168 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1h-hs-cTnI-algorithms
Number of subjects: 392
Study 35189168 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-Atellica
Number of subjects: 392
Study 35189353 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive pain calibration procedure with 24 heat trials
Number of subjects: 171
Study 35189692 — intervention group
Group type: EXPERIMENTAL
Intervention: Social isolation (composite variable based on marital/partner status, religious ties, and community ties)
Number of subjects: 36457
Study 35189692 — intervention group
Group type: EXPERIMENTAL
Intervention: Social isolation with depressive symptoms included in the model
Number of subjects: 36457
Study 35189692 — intervention group
Group type: COMPARATOR
Intervention: Nonisolated women
Number of subjects: 36457